AGM Statement

 | Source: Summit Therapeutics plc Summit Therapeutics plc

Summit Corporation plc
("Summit plc" or "the Company")
 
RESULTS OF ANNUAL GENERAL MEETING                                                                                 
 
Oxford, UK, 9 July 2008 - Summit Corporation plc (AIM: SUMM), a UK biotechnology company, announces that all the resolutions that were proposed to shareholders were passed at its Annual General Meeting held today.  In particular, the following resolutions were approved by shareholders:
 
  •          To increase the authorised share capital of the Company to £7,500,000
  •          The Board has been granted authority to issue new shares up to a nominal value of £1,000,000
  •          To adopt New Articles of Association to reflect changes to English company law
  •          The re-election of the following Directors to the Board of Directors: Steven Lee and Richard Storer
  •          To approve the Reports of the Directors and Auditors and the Accounts for the year ended 31 January 2008.  BDO Stoy Hayward LLP was also reappointed as the Auditors of the Company.
    •  
    - ENDS -
    For more information, please contact:
    Summit plc
    Steven Lee, PhD, Chief Executive Officer
    Darren Millington, ACMA, Chief Financial Officer
    Richard Pye, PhD, Investor Relations
    Tel: +44 (0)1235 443951; +44 (0)7825 313476
    Citigate Dewe Rogerson
    Mark Swallow, PhD / David Dible / Sylvie Berrebi / Emma Palmer
    Tel: +44 (0)207 638 9571
    Panmure Gordon
    Andrew Burnett / Rakesh Sharma (Corporate Finance)
    Ashton Clanfield (Corporate Broking)
    Tel: +44 (0)207 459 3600

    About Summit plc
    Summit plc is a leading UK biotechnology company with a broad preclinical and clinical pipeline, two world-leading technology platforms and an innovative business model that is expected to generate sustainable value for investors.
    Summit is developing multiple drug programmes that target unmet medical needs from which it intends to generate value by out-licensing attractive late preclinical or early clinical stage programmes in return for upfront, milestone and royalty payments. Summit uses its scientific expertise to target orphan diseases, neuro-disorders and infectious diseases.
    Underpinning Summit's drug pipeline are two innovative technology platforms: carbohydrate chemistry and zebrafish biology. These platforms support existing programmes and also will be the source of future programmes to replenish Summit's drug pipeline.  These platform technologies also form the basis of the Company's profitable service business.
    The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM.  Further information about the company is available at www.summitplc.com.